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Background: Depression has been associated with impaired nitric oxide (NO)-mediated vasodilation and
vascular dysregulation (VD). Whether depression and NO levels will disturb retinal haemodynamics is
not clear.
Objectives and methods: Associations between the retinal vasculature, diastolic ocular perfusion pressure
(DOPP) as measure of hypoperfusion, NO metabolites (NOx) and depression symptoms were assessed.
Chronic VD risk markers [depression symptoms (Patient Health Questionnaire/PHQ-9  10) and 24 h
pulse pressure] were determined in a bi-ethnic cohort (n ¼ 313; 48.6 ± 9 years; 53.9% men). At 3 year
follow-up, retinal vessel calibre and retinopathy signs were quantified from digital images. Salivary NOx
was obtained pre- and post-flicker light-induced provocation (FLIP). DOPP was defined as diastolic blood
pressure minus intraocular pressure.
Results: Chronic VD risk was evident in Blacks opposed to acute risk in Whites (P < 0.05). At follow-up,
retinopathy (Blacks 60.4%/Whites 39.6%), lower pre-FLIP (mM) and higher post-FLIP NOx (changes from
baseline, %), arteriolar narrowing and wider venular calibre values were evident in Blacks compared to
Whites, independent of confounders. A wider venular calibre, an index of stroke risk, was associated with
chronic depression symptoms [cut point 248 MU: Area under the curve 0.61 (95% CI: 0.51, 0.72); 71%
sensitivity; 55% specificity] as well as with hypoperfusion in the Blacks. In this group, arteriolar nar-
rowing was associated with hypoperfusion; and attenuated arteriolar dilation with increased post-FLIP
NOx responses.
Conclusions: Chronic depression symptoms may alter NO regulation and facilitate VD. NO-mediated
vasoconstriction presumably impeded perfusion, retinal haemodynamics and eremodelling; potenti-
ating stroke risk in Blacks.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).search Team (HART), North-
t, Private Bag X6001, Potch-
).
Inc. This is an open access article u1. Introduction
The retinal microvasculature shares many features with the
cerebral circulation, such as the presence of a blood-retinal barriernder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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into vascular dysregulation (VD) of the brain [1]. However, the
relationship between chronic conditions such as VD, depression
and hypertension is complex as indicated by opposing findings
[2e5]. Most of these chronic conditions may involve an increased
cardiometabolic risk with apparent depression, inflammation and
perfusion deficits [6e9]. Perfusion deficits increases metabolic
demands in the microvasculature [10], and might explain a mech-
anism linking depression with VD. Taylor et al. indeed demon-
strated that higher metabolic demands and subcortical ischaemia
emerge if VD is evident [11].
VD risk may furthermore be an important pathophysiological
mechanism in South African Blacks as they are more likely to be
diagnosed with symptomatic occlusive vascular disease [12], hy-
pertension, depression and exhibition of enhanced sympathetic
activity, vascular and attenuated norepinephrine responses [13,14].
Indeed, in depressed patients, glucose metabolism in the brain and
norepinephrine turnover was shown to be impaired in subcortical
limbic structures controlling emotions [15]. Therefore, if depression
symptoms are present, vascular pathology in the brain will impose
powerful restraints on ocular perfusion pressure and haemody-
namics [16].
Ocular perfusion pressure is the difference between arterial and
venous blood pressure and is the driving force of ocular blood flow
[17]. Diastolic ocular venous pressure is similar or slightly higher
than intraocular pressure (IOP) [17,18]. Diastolic ocular perfusion
pressure, as marker of hypoperfusion, may therefore be estimated
as the difference between diastolic BP and IOP (DOPP) [18]. In pa-
tients with essential hypertension, increased DOPP via higher blood
pressure and/or lower IOP will enhance vascular resistance and
reduce ocular blood flow to the optic nerve head, thereby inducing
ischaemia and/or hypoxia [19]. VD will thus be present when blood
flow does not adapt to the need of the respective tissues. Retinal
flicker-light-induced provocation (FLIP) therefore might be one
way to directly investigate the dynamic nature of vascular regula-
tion involving the vasodilatory actions of nitric oxide (NO). Para-
sympathetic innervation of the salivary glands contains the NO
synthesizing enzyme, NO synthase [20]. NO secretion of para-
sympathetic origin however, does not seem to take part in the
regulation of the secretory activity [20]. Instead, NO of intracellular
origin is mobilized particularly upon sympathetic nerve activity,
e.g. FLIP and might relate to flicker-induced retinal vasodilation
[20e23]. In Black men, increased a-adrenergic-driven blood pres-
sure responses, less serum NO bio-availability and perfusion defi-
cits were shown during mental stressor exposure [21]. We
therefore hypothesize that less salivary NOx, as non-invasive
measure, may support VD at pre- and post-FLIP phases. A number
of clinical studies additionally support a causal role for neural NO in
depression as altered NO-cyclic guanosine monophosphate (cGMP)
signalling has been proposed as putative biomarker of the
depression response and VD [11,22]. Importantly, this pleiotropic
transmitter has diverse biological effects in the brain and in VD
[23].
Whilst retinal arteriolar narrowing has been associated with VD
and risk for hypertension, a wider venular calibre was associated
with stroke risk [23]. Depression symptoms may relate to VD and
perfusion deficits, thereby accelerating vascular remodelling.
Therefore, we aimed to assess associations between baseline
depression symptoms and retinal vascular regulation under well-
controlled conditions at 3 year follow-up.2. Materials and methods
2.1. Design and participants
The Sympathetic activity and Ambulatory Blood Pressure in
Africans (SABPA) prospective study (Fig. 1) was conducted in 2008/
9 and 2011/12 and described elsewhere [9]. A teachers' cohort
included 409 Black and White men and women from South Africa
of which 359 participated in the 3-year follow-up. Exclusion criteria
[9], for the purpose of the current study, additionally included
epilepsy (n ¼ 4), and poor quality retinal vessel images (n ¼ 42)
yielding a final study sample of 313. Participants were fully
informed about the objectives and procedures prior to recruitment
and provided written, informed consent. The study conformed to
the Helsinki Declaration and was approved by The Ethics Review
Board of the North-West University, Potchefstroom Campus:
Approval number 0003607S6.
Similar to the baseline, clinical assessments were done over a
48 h period at the three-year follow-up [4,9,13]. During theworking
week, 24 h ambulatory blood pressure apparatuses were fitted at
school, a 24 h standardized diet commenced and participants
resumed their normal daily activities. At 15:00, participants were
transported to the North-West University for clinical measures
including retinal vessel imaging and completion of a psychosocial
battery under the supervision of registered clinical psychologists.
Anthropometric measures, 8 h overnight fasting blood sampling
and physical activity measures were obtained the next morning
after 07:00.
2.2. Cardiovascular measures
Ambulatory blood pressure monitoring (ABPM) devices were
attached to participants' non-dominant arm (Meditech CE120
CardioTens®; Meditech, Budapest, Hungary) at school by trained
cardiovascular research personnel. The Cardiotens® was pro-
grammed to measure BP at 30-min intervals during the day
(07:00e22:00) and every hour during night time (22:00e06:00).
The 24 h successful inflation rate at follow-upwas 85.99% (±9.29) in
Africans and 91.80% (±7.95) in Whites. Hypertensive status was
classified as 24 h SBP  130 mm Hg and/or DBP  80 mm Hg [24]
and 24 h pulse pressure (24 h PP) reflecting a hyperpulsatile
pressure, was defined as 24 h SBP e 24 h DBP as a measure of
arterial stiffness. If 24 h PP 50mmHg, the hyperpulsatile pressure
impacts on arterial tone and wall permeability [25].
2.3. Anthropometric and physical activity measures
Anthropometric measurements were performed in triplicate by
level II anthropometrists according to standardized procedures.
Intra- and inter-observer variability was less than 10%. From 07:15
onwards, participants were in a semi-recumbent position. The
ambulatory blood pressure apparatus was removed after the last
recording at 07:30 followed by blood sampling. After all clinical
measures were completed the Actiheart® monitor (GB0/67703,
CamNtech Ltd., Cambridgeshire, UK) was fitted to assess 7 days
physical activity data.
2.4. Depression
Depression symptoms scores were obtained via the PHQ-9
which has 9 items and was validated in various ethnic groups for
use in primary health care settings [26,27]. Each item evaluates the
presence of one of the nine Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV-R) criteria for major
depression. The Cronbach's alpha-reliability index for the total
Baseline
409 enrolled
200 Blacks
3 year follow-up
209 Whites
2170 invited
471 Teachers assessed for eligibility
Aged 20-65 years
173 Blacks 
7 Deceased
20 Losses
186 Whites
2 Deceased
21 Losses
Excluded: 
42 poor retinal vessel 
images
4 epileptic
143 Blacks 170 Whites
Fig. 1. A South African bi-ethnic sex cohort.
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cating good reliability. The recommended and established PHQ-9
cut-off point of 10 indicates the presence of moderately severe
depression symptoms.
2.5. Retinal vessel analyses (function and structure)
Participants abstained from the intake of food or caffeine con-
taining beverages, alcohol, smoking or exercising at least 1 h prior
to measurements. They were introduced to the experimental setup
and screened for acute angle anterior chamber glaucoma risk by a
registered nurse. The retinal vessel analyser (Imedos Systems UG,
Jena, Germany) was used for digital fundus imaging with a Carl
Zeiss FF450Plus camera (Carl Zeiss, Medictech Jena, Germany) to
perform static and dynamic retinal vessel analysis. Mydriasis was
induced in the right eye by a drop containing tropicamide, 1% and
benzalkonium chloride 0.01% (m/v).
a) Dynamic retinal vessel analysis
Flicker-light-induced-provocation (FLIP) (Video clip A.1)
commenced allowing non-invasive measuring of the retinal arte-
rioles and venules diameter responses to the provocation. An op-
toelectronic shutter was inserted in the retinal camera which
interrupted the observation light with a frequency of 12.5 Hz and
wavelength of 530e600 nm. The baseline diameter was measured
for 30 s in continuous light followed by three cycles of 20-s flicker
provocation and 80-s steady fundus illumination. An arteriolar and
venular segment with an average length of 498.7 measuring units
(MU)was subsequentlymeasured.1MU is equivalent to 1 mmwhen
the dimensions of the eye being examined correspond to those of
the normal Gullstrand eye. Changes in ocular haemodynamic
markers were expressed as percentage change over baseline values.
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.niox.2016.02.008.Event blood pressure (Meditech CE120 CardioTens®; Meditech,
Budapest, Hungary) and - salivary sampling were done simulta-
neously, at pre- (baseline, mM) and post-FLIP phases (changes from
baseline calculated in mMand in %). The cuffed armwas relaxed and
placed along the side whilst a salivette cotton swab was simulta-
neously placed in the mouth and passive drooling sampling was
done for 1e2 min (Salimetrics®). The tweezers used to place the
saliva cotton swab (Sarstedt Inc., Leicester, UK) in the mouth, was
kept in a 0.5% chlorhexidine gluconate solution and rinsed with
distilled water before sampling.
b) Static retinal vessel analysis
The Visualis software was used to delineate all vessels' calibre
automatically (VesselMap 2, Version 3.10 software, IMEDOS,
FF450plus, 535e561 nm, 30 image,1840 1360 pixel) (Figure A.1).
The arteriolar calibre (central retinal arteriolar equivalent, CRAE)
and the venular calibre diameters (central retinal venular equiva-
lent, CRVE) were computed and based on the Knudtson big six
formula [28,29] and identified by two experienced scientists. As the
image scale of each eyewas unknown, the values of CRAE and CRVE
were expressed as MU. The reproducibility correlation coefficient
was 0.84 and intra-class correlation Cronbach's alpha-reliability
index for the arteriolar:venular ratio was 0.91 for a randomly
selected cohort.2.6. Diastolic ocular perfusion pressure
A local anaesthetic drop (Novasine Wander 0.4% Novartis) was
inserted in the right eye prior measuring IOP with the Tono-Pen
Avia Applanation Tonometer (Reichert 7-0908, ISO 9001, New
York, USA). The right eye DOPP was calculated (Pre-FLIP DBP e IOP
mmHg) and general retinopathy was diagnosed by a registered
ophthalmologist (Table 3).
Table 1
Clinical characteristic profile of a South African bi-ethnic sex cohort at baseline.
Blacks
(n ¼ 143)
Whites
(n ¼ 170)
P-values
Mean (± SD)
Men 77 (53.9) 81 (47.7) 0.28
Age (years) 44.5 (7.6) 46.4 (9.9) 0.06
Urban living (years) 31.2 (16.1) 20.8 (12.8) <0.001
Cholesterol (mmol/l) 4.7 (1.2) 5.6 (1.3) <0.001
Cardiometabolic clinical characteristics Count (prevalence %)
CVD History 13 (40.6) 19 (59.4) 0.54
Active smoking 38 (26.8) 22 (12.9) 0.002
Alcohol abuse 77 (54.2) 24 (14.1) 0.001
Central obesity 91 (63.6) 108 (63.5) 0.98
Depression symptoms (PHQ-9) 50 (35.0) 18 (10.6) <0.001
Pre-diabetes 87 (61.7) 53 (31.2) <0.001
Low grade inflammation 92 (64.8) 48 (28.2) 0.001
Arterial stiffness 49 (8.8) 48 (7.1) 0.33
Hypertension 94 (65.7) 73 (42.9) <0.001
Hypertension with Depression symptoms 41 (28.67) 9 (5.29) <0.001
Medications Count (prevalence %)
Statins 2 (1.4) 8 (4.7) 0.1
Aspirin 2 (1.4) 12 (7.1) 0.02
Hypertension 50 (13.9) 58 (16.2) <0.001
Abbreviations: CVD, history of cardiovascular disease; Active smoking
(Cotinine > 50 ng/ml) [31]; Alcohol abuse (gamma-glutamyl transferase  41 U/l)
[32]; PHQ-9  10, Patient Health Questionnaire [26]; Central obesity, waist 94 cm
men and 80 cm women [30]; Pre-diabetes, HbA1C  5$7 [30]; Low grade
inflammation, CRP  3U/L [24]; Arterial stiffness, 24 h pulse pressure  50 mmHg
[25]; Hypertension, SBP  130 and/or DBP  80 mmHg [24].
Table 2
Cardiometabolic profile changes over 3 years in a Black and White Sou
Blacks
follow-up (n ¼ 143
D % [OR: 95% CI], P
CVD History 2.8 [1.7: 0.6e4.6], 0
Active smoking 7.2 [6.0: 1.3e26.8],
Alcohol abuse 9.4 [2.4: 1.1e5.3], 0
Central obesity 5.0 [2.4: 0.9e6.8], 0
Depression symptoms 1.4 [1.1: 0.6e1.9], 0
Pre-diabetes 2.9 [1.3:0.6e2.5], 0
Low grade inflammation 5.7 [1.8:0.8e3.9], 0
Arterial stiffness 8.4 [2.2: 1.0e4.7], 0
Hypertension 1.4 [1.2: 0.6e2.4], 0
aRetinal vascular regulation characteristics Mean (±SD)
Retinopathology, n (%) 99 (60.4)
R-Arteriolar calibre (MU) 149.64 ± 12.98
R-Venular calibre (MU) 250.34 ± 19.88
R-DOPP (mmHg) 71.17 ± 12.43
R-Arteriolar dilation (%) 4.38 ± 2.58
R-Venular dilation (%) 5.15 ± 2.36
Pre-FLIP SBP/DBP (mmHg) 140/88 ± 20/12
Post-FLIP SBP/DBP (mmHg) 139/88 ± 19/13
Pre-FLIP NOx (mM) 253.01 ± 200.15
Post-FLIP NOx (mM) 308.94 ± 212.08
Post-FLIP NOx (%) 42.54 ± 76.72
Medications D % [OR: 95% CI], P
Hypertension 3.5 [1.4: 0.7e2.8], 0.47
Statins 0.0 [1.0: 0.1e7.0], 0.1
Aspirin 14.0 [21.0: 2.8e156.1],
Anti-depressants 0
Abbreviations: CVD, history of cardiovascular disease; Active smokin
transferase  41 U/l) [32]; PHQ-9  10, Patient health Questionnaire [2
Pre-diabetes, HbA1C  5$7 [30]; Low grade inflammation, CRP  3U
Hypertension, SBP  130 and/or DBP  80 mmHg [24]; R, right; DOP
provocation; NOx, nitric oxide provocation.
a Available at follow-up only.
Table 3
Ocular media and fundus assessment at 3 year follow-up.
Blacks
(n ¼ 143)
Whites
(n ¼ 170)
P-values
Count (prevalence %)
Men 77 (53.9) 81 (47.7) 0.28
Age (years) 44.5 (7.6) 46.4 (9.9) 0.06
Acute anterior glaucoma risk 0 (0.00) 14 (8.24) <0.001
Retinopathology 99 (69.23) 65 (38.24) <0.001
Retinal atrophy 0.(0.0) 2 (1.18) 0.20
Retinal scarring 1 (0.70) 0 (0.00) 0.26
Drusen 1 (0.70) 0 (0.00) 0.27
Ciliary blood vessels 1 (0.70) 0.(0.00) 0.27
Microaneurysm 7 (4.90) 0 (0.00) 0.003
Exudates 2 (1.40) 0 (0.00) 0.12
Arteriovenous nicking 90 (62.94) 38 (22.35) <0.001
Cotton wool spots 2 (1.40) 0 (0.00) 0.11
Focal narrowing 6 (4.20) 0 (0.00) 0.06
Macula scarring 0 (0.00) 1 (0.59) 0.37
Optic head (cup:disc ratio > 0.50) 29 (20.28) 32 (18.82) 0.55
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Sodium fluoride glucose, serum and whole blood plasma sam-
ples were analysed for lipids, high sensitivity C-reactive protein
(CRP), gamma-glutamyl transferase (g-GT), cotinine, and glycated
haemoglobin (HbA1C) respectively [30e32] using the Cobas Integra
400 Plus and the Modular ROCHE Automized systems (Basel,
Switzerland). Intra- and inter-assay coefficients were less than 10%.
Saliva NOx analyses based on the enzymatic conversion of nitrate toth African cohort.
)
Whites
follow-up (n ¼ 170)
.46 6.5 [2.8: 1.1e7.2], 0.04
0.06 1.8 [4.0: 0.5e35.8)], 0.38
.02 4.0 [4.5: 1.0e20.8], 0.67
.14 11.2 [5.8: 2.0e16.6], 0.001
.89 6.6 [2.6: 1.1e6.2], 0.04
.61 10.7 [2.8: 1.4e5.8], 0.01
.19 8.2 [2.6: 1.2e5.5], 0.02
.05 1.8 [1.2: 0.6e2.2], 0.81
.85 7.1 [5.8: 1.0e3.6], 0.88
P-Values
65 (39.6) <0.001
151.22 ± 11.48 0.28
237.01 ± 18.02 <0.001
68.17 ± 10.74 0.02
4.02 ± 2.05 0.17
4.56 ± 1.96 0.02
133/83 ± 15/11 <0.001
132/83 ± 14/10 <0.001
334.63 ± 243.05 0.02
342.48 ± 213.13 0.11
14.70 ± 48.34 <0.001
7.7 [2.6: 1.2e5.9], 0.02
11.8 [21.0: 2.8e156.0], 0.001
0.001 5.9 [3.5: 1.2e10.6], 0.03
0
g (Cotinine > 50 ng/ml) [31]; Alcohol abuse (gamma-glutamyl
6]; Central obesity, waist 94 cm men and 80 cm women [30];
/L [24]; Arterial stiffness, 24 h pulse pressure  50 mmHg [25];
P, diastolic ocular perfusion pressure; FLIP, flicker light-induced
L. Malan et al. / Nitric Oxide 55-56 (2016) 10e1714nitrite by nitrate reductase included clorimetric detection of nitrite
(Griess Reaction, 540 nm) with inter- and intra-assay variability of
2.4e7.7% and 1.5e5.5% respectively (product code 10752345;
Thermo Scientific, Pierce Biotechnology, IL, USA).
2.8. Statistical analysis
Statistica® software version 12.0 (Statsoft Inc., Tulsa, USA, 2012)
and SPSS (SPSS Inc., IBM SPSS Statistics Version 22, Release 22.0.0,
2015, Copyright© IBM Corporation and its licensors) were used for
data analyses. Normal distribution was evident when standard er-
rors of kurtosis and skewness did not exceed the value itself by
twofold. Logarithmical transformationwas deemed appropriate for
CRP, cotinine and g-GT. Independent t and Chi-square (c2) tests
compared ethnic differences and prevalence at baseline. McNe-
mar's case-control tests were used to demonstrate potential VD risk
markers prevalence and change in risk (D %) over 3 years. Recog-
nized a priori confounders included sex, age, log g-GT, log cotinine,
log CRP, glucose and cholesterol [24]. General linear models
determined interaction on main effects (ethnic by sex) at follow-up
for depression symptoms and retinal VD risk markers, independent
of a priori confounders. After a priori hypotheses for all tests were
performed, general linear models followed by comparing depres-
sion symptoms and retinal VD risk markers in ethnic groups. We
used least square means and considered a priori confounders.
Forward stepwise regression analyses investigated associations
between retinal vascular function and structure, perfusion, NOx
and chronic depression symptoms. Dependent variables included
static and functional analyses of retinal arterioles and venules. In-
dependent covariates included: a priori, baseline depression
symptoms (indicative of chronic depression), DOPP, 24 h pulse
pressure, retinopathy prevalence, pre- and post-FLIP NOx values. As
result of the high correlation between CRAE and CRVE, CRAE was
added as covariate for CRVE and vice versa. Sensitivity analyses
were conducted to additionally control for cardiovascular disease
(CVD) history, hypertension medication and HIV infection.
Optimal venular cut points associated with chronic depression
symptomswere computed from the maximum of the Youden index
(J) (sensitivity þ specificity  1) using non-parametric receiver
operating characteristic (ROC) curves. The statistical significance
level was set at p  0.05 (two-tailed).
3. Results
Ethnic differences were evident for retinal arteriolar narrowing
(F1,289 ¼ 11.11, P < 0.001) as well as chronic depression symptoms
(F1,313 ¼ 10.26, P ¼ 0.002). In Table 1, Blacks showed car-
diometabolic susceptibility with more smoking, alcohol consump-
tion, depression symptoms, increased pre-diabetes, low-grade
inflammation and hypertension compared to Whites at baseline.
In Table 2, it is clear that Blacks showed chronic as opposed to
acute VD risk in the Whites for depression symptoms, inflamma-
tion, pre-diabetes and 24 h hypertension. The Blacks showed
increased alcohol abuse and arterial stiffness (-tone) risk over 3
years. This was accompanied by wider venular diameter and ven-
ular dilation, DOPP, pre-FLIP BP and -Nox (mM), as well as post-FLIP
BP values and -NOx (%) responses, at follow-up. In Table 3, higher
retinopathy prevalence (60.4%) compared to Whites (39.6%;
P < 0$001) included more arteriovenous nicking, micoraneurysms
but less acute anterior glaucoma risk.
General linear models (ANCOVAs) considering a priori con-
founders in Fig. 2, revealed more depression symptoms, potential
vascular disease with arterial narrowing and wider venular cali-
bres, lower pre-FLIP NOx values and higher post-FLIP NOx (%) re-
sponses in Blacks.In Fig. 3, a wider venular calibre cut point was associated with
chronic depression symptoms in the Blacks only [248 MU: Area
under the curve 0$61 (95% confidence interval/CI: 0$51, 0$72);
71% sensitivity; 55% specificity]. In Table 4, inverse associations
existed between increased DOPP and arteriolar calibre in Blacks
and Whites. A wider venular calibre, with cut point of 248 MU
(Fig. 3) was associated with both hypoperfusion (increased
DOPP) and chronic depression symptoms in the Blacks only. In
this group, arteriolar narrowing was associated with hypo-
perfusion whilst attenuated arteriolar dilation was associated
with increased post-FLIP NOx responses in the Blacks only [(Adj
R2 0.21; b 0.16 (0.3, 0.0), P ¼ 0.05)]. Repeating multiple
regression analyses to control for cardiovascular disease (CVD)
history, hypertension medication and HIV infection did not
change the outcome.
4. Discussion
Firstly, chronic depression in the Blacks rather than acute
depression in the Whites were accompanied by retinal vascular
pathology. Secondly, VD seems more apparent in the Black cohort,
where increased post-FLIP NOx responses were associated with
attenuated arteriolar vasodilation, a notion of endothelial
dysfunction. Lastly, a wider venular calibre (248 MU cut point), an
index of stroke risk, was associatedwith hypoperfusion and chronic
depression in Blacks. These three factors (chronic depression,
dysregulated NO and retinal vessel haemodynamics) can facilitate
VD [11] in the Blacks.
4.1. Depression and VD
The presence of a blood-retinal barrier may provide some
insight into cerebrovascular pathology [1,8,11,18,19,33], subcortical
ischaemia [11] and perfusion deficits in the ocular media [10].
Therefore, chronic symptoms of depression, pre-diabetes, low-
egrade inflammation and hyperpulsatile pressure (vascular tone/
stiffness) prevalence in the Black cohort may potentiate retinal
vascular pathology. Sustained VD susceptibility in this cohort may
have emerged due to higher metabolic demands (oxygen and
glucose) in the brain when elevated symptoms of depression are
present. Lambert et al. support this notion, having demonstrated
reduced cerebral respiratory quotient in depressed subjects [15].
Chronic depression symptoms thus impair metabolism in limbic
areas associated with depression [11,34] that in turn may be asso-
ciated with altered NO metabolism leading to central and retinal
perfusion deficits and -structural changes.
Meier et al. [34] and Jensen et al. [8] support the associations
between depression and structural changes in the retinal vascular
calibres. However, for the first time we now show that chronic
depression symptoms and bio-available salivary NO may facilitate
retinal functional and structural dysregulation. Over-demanding
emotional challenges activate sympatho-adrenal medullary (SAM)
and hypothalamic-pituitary-adrenal cortical axis (HPAA) stress
pathway responses and can facilitate chronic depression symptoms
[11,35]. Indeed, evidence of chronic disturbed metabolism seems
plausible in the Blacks, as they presented cardiometabolic vulner-
ability, depression symptoms and compensatory post-FLIP induced
neural NO release. On related note, higher sympathetic activity was
shown to be present in around 30% of depressed patients [35]. In
agreement, the SABPA Black cohort has demonstrated attenuated
acute stress pathway reactivity responses when having depression
symptoms [14], which support the notion of habituation of neuro-
endocrine pathways, resulting in disturbed metabolism and inev-
itable neural fatigue [9]. Ultimately, chronic and not acute
depression symptoms accompanied by a hyperpulsatile pressure/
ab
*
*
0
1
2
3
4
5
6
7
8
9
Depression symptoms Arteriolar dilation, % Venular dilation, %
Blacks (N=143) Whites (N=170)
*
*
*
*
0
50
100
150
200
250
300
350
400
Arteriolar
caliber,   MU
Venular
caliber,     MU
DOPP,
mmHg
Pre-FLIP
Nox, μM
Post-FLIP
Nox, μM
Post-FLIP
Nox, %
Fig. 2. (a & b): Depression symptoms and vascular disease risk in Black vs. White Africans (mean ± standard error of mean), independent of covariates. Covariates included age, sex,
log cotinine, log GGT, log CRP, cholesterol and glucose. When retinal arteriole calibre was a dependent variable, retinal venular calibre was included and vice versa. Abbreviations:
DOPP, diastolic ocular perfusion pressure; FLIP, flicker light-induced provocation; %, salivary NOx mean changes during FLIP and adjusted for baseline values; NOx, nitric oxide
metabolites. *P  0.05.
Fig. 3. The optimal retinal venular cut point associated with chronic depression
symptoms in a Black sex cohort. Where: AUC, area under the curve; CI, confidence
interval with 71% sensitivity, 55% specificity.
L. Malan et al. / Nitric Oxide 55-56 (2016) 10e17 15vascular tone in the Black cohort may have facilitated VD. Our
findings underscore the importance of chronic and not acute
increased metabolic demands for associated VD as similar associ-
ations were not found in the Whites who demonstrated acute
depressive symptoms.
VD may further increase if ocular perfusion pressure [28] isdisturbed as it is the driving force to ascertain sufficient blood flow
through the ocular vasculature to nourish retinal neurons [17].
Blood flow in the ocular blood vessels will be modified by changes
in the microvascular calibre. Therefore any changes in the retinal
vascular calibre may affect ocular blood flow which was demon-
strated in our Black cohort who presented a mean profile of chronic
hypertension and more retinopathy signs, such as more micro-
aneurysms and arteriovenous nicking. Their chronic higher
hyperpulsatile pressure may further increase DOPP, augment
vascular resistance and reduce ocular blood flow to retinal tissue
thereby inducing ischaemia and/or hypoxia. Over time it may
manifest as functional arteriolar narrowing [18,19,22].
A profile of chronic depression symptoms and disturbed
vascular function may further impede perfusion, driven by chronic
hyperpulsatile pressure. The notion of increased perfusion pressure
enforces contraction in the ocular arteries, which are resistance
vessels and regulated by myogenic mechanisms (Bayliss effect)
[35]. In the Blacks however, myogenic tone may be impaired during
chronic hypertension and -depression symptoms when less bio-
available NO is evident, as distal capillaries are not protected
against deleterious increases in hyperpulsatile pressure [18]. To
maintain autoregulation and perfusion, compensatory increases in
neural to blood vessels signalling or neurovascular coupling, will
enhance vascular tone (pulse pressure) and increase post-FLIP NOx
with arteriole dilation. However, our findings contradict this
mechanism and we reject the hypothesis of higher NOx coupled to
increased retinal arteriolar vasodilation. The potent vasodilatory
effects of NO, modulating neurovascular coupling, seems to be
inhibited and vasoconstriction [36] or impaired arteriolar dilation
Table 4
Forward stepwise regression analyses depicting associations between retinal vasculature, chronic depression symptoms, hypoperfusion and NOx responses.
Blacks (n ¼ 143)
Artery dilation, % Artery calibre, MU Vein dilation, % Vein calibre, MU
Adjusted R2 0.21 0.37 <0.10 0.30
b (95% CI), P
Sex e e e 0.22 (0.4,0.1), 0.01
Chronic depression symptoms e e e 0.18 (0.0,0.3), 0.03
DOPP, mmHg e 0.46 (0.6,0.3), <0.001 e 0.20 (0.0,0.4), 0.04
Saliva Pre-FLIP NOx (mM) e e e 0.15 (0.0,0.3), 0.07
Saliva Post-FLIP NOx (mM) 0.16 (0.3,0.0), 0.05 e e e
Whites (n ¼ 170)
Adjusted R2 <0.10 0.47 <0.10 0.47
b (95% CI), P e
Sex e e e e
Chronic depression symptoms e e e e
DOPP, mmHg e 0.20 (0.3,0.1), <0.001 e e
Salivary Pre-FLIP NOx (mM) e e e e
Salivary Post-FLIP NOx (mM) e e e e
Where F to enter ¼ 2.5. Covariates included age; log -GGT; log cotinine; log CRP; cholesterol; glucose; when retinal arteriole calibre was a dependent variable, retinal venular
calibre was included and vice versa. Abbreviations: DOPP, diastolic ocular perfusion pressure; chronic depression symptoms, baseline depression symptoms; FLIP, flicker light
induced provocation, NOx, nitric oxide metabolites.
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vasodilation is not certain. Impaired myogenic tone may increase
retinal venular widening especially during chronic pressure over-
load and we cautiously suggest that an overactive sympathetic
system and/or chronic depression symptoms might explain part of
the mechanism.
4.2. NOx bio-availability and microvasculature susceptibility
In patients with depression, a reduction in NO bio-availability
was associated with impairment in vasodilation [37] as they
showed less uptake and utilisation of amino acids such as L-argi-
nine, the precursor of NO [38]. Indeed, we have previously
demonstrated that the L-arginine/NO system in the black SABPA
cohort is affected by emotional distress [39]. Therefore, the inability
to generate sufficient NO to overcome vascular resistance in retinal
vessels may increase the risk in Blacks for diseases such as stroke
and peripheral occlusive vascular disease [22,40].
Increased neural responses in the Blacks via activation of the
SAM and HPAA stress pathways during the FLIP may thus have
facilitated NOx release to maintain perfusion. In chronic car-
diometabolic vulnerable conditions, bio-availability of NO can
further be attenuated as was observed in Blacks compared to
Whites. Indeed, the lower bio-available pre-FLIP saliva NOx levels
in the Blacks appear to be the regulating factor for retinal VD and
subsequent ischaemia. A compromised NO synthase system may
affect downstream nitrite production in glia cells and strain
subcortical metabolism. With higher central metabolic demands,
superoxide increases that in turn lowers NOx and NO to induce VD
[41]. The increased NOx post-FLIP levels oppose findings of lower
serum NOxmental stress levels from another bi-ethnic SABPAmale
cohort [21]. Therefore, saliva NOx as neural source of NO might
prove to be an improved marker as opposed to serum or urine for
retinal vascular regulation assessment during a challenged sym-
pathetic system.
4.3. Central control: compensatory haemodynamics and stroke risk
Esler et al. proposed that chronic mental stress is a cause of
essential hypertension [41]. We support these findings as chronic
cardiometabolic vulnerability i.e., depression symptoms in
conjunction with a hypertensive state is more prevalent in Blacksthan in Whites (28.67% vs. 5.29$%; P  0.001). This profile will in-
crease neural drive in the brain during demanding chronic situa-
tions [7], decreasing sensitivity in organ structures such as the
retina to prevent vascular pathology [11,18]. The high prevalence of
hypertension in Blacks (66%) may thus influence autoregulation
and vasomotor tone, favouring increased vascular resistance
(arteriolar vasoconstriction) and possibly, vessel closure in the
microcirculation [42]. On-going uncontrolled systemic hyperten-
sion and perfusion pressure in the Blacks may thus pose a risk of
injury to the optic nerve head, retinal ganglion cells and thus lead to
the development of retinopathy [43].
A key limitation is that retinal vascular datawere not available at
baseline and thereforewe can't confirm that these vascular changes
were not already apparent earlier on. Flammer et al. also suggested
that ocular venous pressure rather than DOPP is preferred as
measure of hypoperfusion and should be obtained when VD is
present [18]. The contribution of autonomic dysfunction to delin-
eate possible physiological mechanisms at play needs to be
explored. More objective measures such as functional MRI's to
substantiate subcortical ischaemia and perfusion deficits are
needed.
In conclusion, a profile of chronic depression and car-
diometabolic susceptibility may disturb the regulation of NO syn-
thesis resulting in the observed changes in NOx and thus facilitate
VD [7]. Subsequent increases in hyperpulsatile pressure may
counteract reduced ocular perfusion thereby impairing myogenic
tone and vascular regulation. Screening of diastolic ocular perfusion
pressure and for the presence of depression symptoms is recom-
mended to detect early onset of vascular pathology and potential
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